An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL

References

• Tan SH, Bertulfo FC, Sanda T. Leukemia-initiating cells in T-cell acute lymphoblastic leukemia. Front Oncol. 2017;7:218.
   PubMed Web of Science ®Google Scholar
• El Fakih R, Ahmed S, Alfraih F, et al. Hematopoietic cell transplantation for acute lymphoblastic leukemia in adult patients. Hematol Oncol Stem Cell Ther. 2017;10(4):252–258.
   PubMedGoogle Scholar
• Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol. 2008;8(5):380–390.
   PubMed Web of Science ®Google Scholar
• Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016;16(8):494–507.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–983.
   PubMed Web of Science ®Google Scholar
• Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059–1064.
   PubMed Web of Science ®Google Scholar
• Bongiovanni D, Saccomani V, Piovan E. Aberrant signaling pathways in T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2017;18(9):E1904.
   PubMed Web of Science ®Google Scholar
• Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551–565.
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–543.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–2041.
   PubMed Web of Science ®Google Scholar
• Durinck K, Goossens S, Peirs S, et al. Novel biological insights in T-cell acute lymphoblastic leukemia. Exp Hematol. 2015;43(8):625–639.
   PubMed Web of Science ®Google Scholar
• Byrns MC, Jin Y, Penning TM. Inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. J Steroid Biochem Mol Biol. 2011;125(1–2):95–104.
   PubMed Web of Science ®Google Scholar
• Guise CP, Abbattista MR, Singleton RS, et al. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 2010;70(4):1573–1584.
   PubMed Web of Science ®Google Scholar
• Oduwole OO, Li Y, Isomaa VV, et al. 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res. 2004;64(20):7604–7609.
   PubMed Web of Science ®Google Scholar
• Penning TM. Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). J Steroid Biochem Mol Biol. 2015;153:105–113.
   PubMed Web of Science ®Google Scholar
• Jamieson SM, Gu Y, Manesh DM, et al. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochem Pharmacol. 2014;88(1):36–45.
   PubMed Web of Science ®Google Scholar
• Desmond JC, Mountford JC, Drayson MT, et al. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res. 2003;63(2):505–512.
   PubMed Web of Science ®Google Scholar
• Khanim F, Davies N, Velica P, et al. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate. Br J Cancer. 2014;110(6):1506–1516.
   PubMed Web of Science ®Google Scholar
• Verma K, Zang T, Gupta N, et al. Selective AKR1C3 inhibitors potentiate chemotherapeutic activity in multiple acute myeloid leukemia (AML) cell lines. ACS Med Chem Lett. 2016;7(8):774–779.
   PubMed Web of Science ®Google Scholar
• Verma K, Zang T, Penning TM, et al. Potent and highly selective aldo-keto reductase 1C3 (AKR1C3) inhibitors act as chemotherapeutic potentiators in acute myeloid leukemia and T-cell acute lymphoblastic leukemia. J Med Chem. 2019;62(7):3590–3616.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Lin CC, et al. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2011;68(2):539–545.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Thall PF, Yi CA, et al. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015;100(7):927–934.
   PubMed Web of Science ®Google Scholar
• Evans K, Duan J, Pritchard T, et al. OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL. Clin Cancer Res. 2019;25(14):4493–4503.
   PubMed Web of Science ®Google Scholar
• Flanagan JU, Atwell GJ, Heinrich DM, et al. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-beta-hydroxysteroid dehydrogenase (AKR1C3). Bioorg Med Chem. 2014;22(3):967–977.
   PubMed Web of Science ®Google Scholar
• Huang Q, Zhou C, Chen X, et al. Prodrug AST-003 improves the therapeutic index of the multi-targeted tyrosine kinase inhibitor sunitinib. PLOS One. 2015;10(10):e0141395.
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6.
   PubMed Web of Science ®Google Scholar
• Moradi Manesh D, El-Hoss J, Evans K, et al. AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood. 2015;126(10):1193–1202.
   PubMed Web of Science ®Google Scholar
• Andersson A, Ritz C, Lindgren D, et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia. 2007;21(6):1198–1203.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Kohlmann A, Wieczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;28(15):2529–2537.
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Kang H, Moskowitz NP, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood. 2006;108(2):711–717.
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011;117(23):6267–6276.
   PubMed Web of Science ®Google Scholar
• Raetz EA, Perkins SL, Bhojwani D, et al. Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer. 2006;47(2):130–140.
   PubMed Web of Science ®Google Scholar
• Kirschner-Schwabe R, Lottaz C, Todling J, et al. Expression of late cell cycle genes and an increased proliferative capacity characterize very early relapse of childhood acute lymphoblastic leukemia. Clin Cancer Res. 2006;12(15):4553–4561.
   PubMed Web of Science ®Google Scholar
• Ping H, Chunnian W, Yanlan W, et al. A novel aldo-keto reductase AKR1C3 specific prodrug TH-3424 with potent anti-tumor activity. DOI:10.1002/cpt.1708
   Google Scholar
• Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005;21(13):2933–2942.
   PubMed Web of Science ®Google Scholar
• Abbattista MR, Jamieson SM, Gu Y, et al. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma. Cancer Biol Ther. 2015;16(4):610–622.
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Jameson MB, Ramanathan RK, et al. PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours. BMC Cancer. 2012;12(1):496.
   PubMedGoogle Scholar
• McKeage MJ, Gu Y, Wilson WR, et al. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer. 2011;11(1):432.
   PubMedGoogle Scholar
• Jameson MB, Rischin D, Pegram M, et al. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol. 2010;65(4):791–801.
   PubMed Web of Science ®Google Scholar
• Nombela-Arrieta C, Silberstein LE. The science behind the hypoxic niche of hematopoietic stem and progenitors. Hematol Am Soc Hematol Educ Program. 2014;2014(1):542–547.
   PubMedGoogle Scholar
• Chen H, Yang T, Zhu L, et al. Cellular metabolism on T-cell development and function. Int Rev Immunol. 2015;34(1):19–33.
   PubMed Web of Science ®Google Scholar
• Birtwistle J, Hayden RE, Khanim FL, et al. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat Res. 2009;662(1–2):67–74.
   PubMed Web of Science ®Google Scholar